Ameriprise Financial Inc. raised its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 59.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,003 shares of the medical research company’s stock after buying an additional 30,089 shares during the period. Ameriprise Financial Inc. owned about 0.24% of Genomic Health worth $2,636,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of GHDX. Renaissance Technologies LLC boosted its stake in shares of Genomic Health by 27.1% during the 1st quarter. Renaissance Technologies LLC now owns 733,200 shares of the medical research company’s stock valued at $23,088,000 after buying an additional 156,500 shares during the period. Vanguard Group Inc. boosted its stake in shares of Genomic Health by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock valued at $49,256,000 after buying an additional 126,807 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Genomic Health by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock valued at $9,259,000 after buying an additional 81,425 shares during the period. Cowen Prime Services LLC boosted its stake in shares of Genomic Health by 324.1% during the 2nd quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock valued at $2,885,000 after buying an additional 67,735 shares during the period. Finally, Eagle Asset Management Inc. lifted its stake in shares of Genomic Health by 18.4% in the 2nd quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after purchasing an additional 58,920 shares during the last quarter. 88.90% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Ameriprise Financial Inc. Raises Holdings in Genomic Health, Inc. (GHDX)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/10/31/ameriprise-financial-inc-raises-holdings-in-genomic-health-inc-ghdx.html.
In other Genomic Health news, insider James J. Vaughn sold 8,000 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total value of $244,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $30.57, for a total transaction of $152,850.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,000 shares of company stock valued at $1,022,620. Corporate insiders own 46.20% of the company’s stock.
Shares of Genomic Health, Inc. (GHDX) opened at 32.70 on Tuesday. The company has a 50 day moving average of $32.19 and a 200 day moving average of $31.82. Genomic Health, Inc. has a 1-year low of $26.37 and a 1-year high of $34.02. The firm’s market cap is $1.13 billion.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The firm had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.18) EPS. On average, equities analysts forecast that Genomic Health, Inc. will post ($0.04) earnings per share for the current fiscal year.
Several research firms recently issued reports on GHDX. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research note on Wednesday, September 27th. BidaskClub lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research note on Friday, October 20th. Finally, Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $32.00.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
What are top analysts saying about Genomic Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health Inc. and related companies.